Healthcare provider profile · identity verified

Barry J. Bugatto, MD

Internal Medicine · SAN FRANCISCO, CA · NPI 1356429906

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	676	216
Amlodipine Besylate	Amlodipine Besylate	240	81
Losartan Potassium	Losartan Potassium	222	75
Atenolol	Atenolol	196	61
Lisinopril	Lisinopril	186	57
Levothyroxine Sodium	Levothyroxine Sodium	183	54
Tamsulosin Hcl	Tamsulosin Hcl	175	65
Famotidine	Famotidine	159	53
Omeprazole	Omeprazole	149	51
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	147	47
Furosemide	Furosemide	139	49
Hydrochlorothiazide	Hydrochlorothiazide	130	44
Fluticasone Propionate	Fluticasone Propionate	117	48
Metformin Hcl Er	Metformin Hcl	107	42
Albuterol Sulfate Hfa	Albuterol Sulfate	106	51
Gabapentin	Gabapentin	102	39
Meloxicam	Meloxicam	99	61
Metoprolol Tartrate	Metoprolol Tartrate	97	32
Pantoprazole Sodium	Pantoprazole Sodium	90	30
Metformin Hcl	Metformin Hcl	89	29
Alendronate Sodium	Alendronate Sodium	88	26
Metoprolol Succinate	Metoprolol Succinate	87	30
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	86	14
Allopurinol	Allopurinol	79	27
Alvesco	Ciclesonide	79	27
Finasteride	Finasteride	77	24
Zolpidem Tartrate	Zolpidem Tartrate	72	12
Hydralazine Hcl	Hydralazine Hcl	69	20
Simvastatin	Simvastatin	59	20
Jardiance	Empagliflozin	56	20
Lovastatin	Lovastatin	55	16
Trazodone Hcl	Trazodone Hcl	49	14
Lorazepam	Lorazepam	48	14
Terazosin Hcl	Terazosin Hcl	46	15
Pradaxa	Dabigatran Etexilate Mesylate	45	16
Clobetasol Propionate	Clobetasol Propionate	43	23
Triamcinolone Acetonide	Triamcinolone Acetonide	43	25
Colchicine	Colchicine	39	15
Glipizide	Glipizide	39	12
Acyclovir	Acyclovir	38	16
Fluoxetine Hcl	Fluoxetine Hcl	38	12
Prednisone	Prednisone	37	25
Nabumetone	Nabumetone	34	15
Rosuvastatin Calcium	Rosuvastatin Calcium	32	suppressed
Citalopram Hbr	Citalopram Hydrobromide	30	suppressed
Mirtazapine	Mirtazapine	30	11
Potassium Chloride	Potassium Chloride	29	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	28	21
Hydrocortisone	Hydrocortisone	28	12
Midodrine Hcl	Midodrine Hcl	26	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Oxazepam	Oxazepam	24	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Ipratropium Bromide	Ipratropium Bromide	23	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	23	21
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	23	suppressed
Carvedilol	Carvedilol	22	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Naproxen	Naproxen	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Amoxicillin	Amoxicillin	20	16
Glipizide Er	Glipizide	20	suppressed
Ozempic	Semaglutide	20	suppressed
Duloxetine Hcl	Duloxetine Hcl	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Cefadroxil	Cefadroxil	18	16
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	17	17
Metronidazole	Metronidazole	17	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	17	suppressed
Spiriva Respimat	Tiotropium Bromide	16	suppressed
Azithromycin	Azithromycin	15	12
Humulin N	Insulin Nph Human Isophane	14	suppressed
Oxycontin	Oxycodone Hcl	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Alprazolam	Alprazolam	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Diclofenac Sodium Er	Diclofenac Sodium	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Modafinil	Modafinil	12	suppressed
Montelukast Sodium	Montelukast Sodium	12	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error